Research programme: anti-cancer antibodies - Tikro/Weizmann

Drug Profile

Research programme: anti-cancer antibodies - Tikro/Weizmann

Latest Information Update: 11 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Tikcro Technologies; Weizmann Institute of Science
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Jun 2018 Research programme: anti-cancer antibodies - Tikro/Weizmann is available for licensing as of 06 Jun 2018. https://tikcro.com/
  • 08 Sep 2017 Tikcro plans an in-vivo animal studies in 2017 and IND enabling pre-clinical studies in 2018 for cancer
  • 15 Jun 2015 Preclinical trials in Cancer in Israel (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top